Browse the corpus

The recommended dose of imdevimab is 600 mg, along with casirivimab 600 mg. In studies, doses up to 8 g (4000 mg of each drug) have been administered without dose-limiting toxicity. In overdose situations, general supportive measures, including vital signs and clinical status monitoring, are recommended. There is no specific antidote for toxicity due to overdose. Pregnancy and lactation: Imdevimab is a humanized monoclonal antibody (IgG1). Placental transfer of IgG depends on different factors, such as maternal serum IgG level and IgG subclass.[10] Further data are needed to classify risk or benefit to the fetus. Maternal IgG is present in breast milk. Imdevimab is a large protein molecule with a molecular weight of about 144,000 Da, so the amount in milk is probably low. It is also likely partially destroyed in the infant's gastrointestinal tract. Therefore, absorption by the infant is likely low. No information is available regarding the use of imdevimab during breastfeeding. According to the emergency use authorization, the decision to breastfeed during therapy should depend on the benefit of treatment of the mother and the benefits and risk of exposure to the infant. No dose adjustment is recommended for pregnant or lactating patients per emergency use authorization by the FDA (FDA 2021).[11]

Imdevimab is a new monoclonal antibody authorized for emergency use by the FDA due to the ongoing COVID-19 pandemic. As a novel agent, all interprofessional healthcare team members involved in patient care need to be up to speed on the latest information regarding the use of this drug. Initial results show a decreasing viral load and clinical benefit if the drug is initiated early in high-risk patients with mild to moderate disease.[9] More adverse effects related to the drug might be reported in the future. Therefore, when the drug is being used, close safety monitoring is needed by the prescribing clinician and the nurses and pharmacists. Providers should be vigilant of any potential drug-related adverse effects. The patient's education regarding the drug is crucial. The drug combination is administered via intravenous infusion or SQ, and there is the possibility of infusion and injection-related side effects, including pyrexia, chills, urticaria, pruritis, abdominal pain, and flushing, along with hypersensitivity and anaphylaxis. Observation in the infusion center after transfusion for at least 60 minutes is recommended. The interprofessional team of healthcare professionals must have the necessary medications and equipment in the room to ensure safe outcomes. Proper and prompt intervention can be life-saving in cases of something as serious as anaphylaxis.[7] Pharmacists can help clinicians and nurses ensure proper dosing, monitor drug interactions, and educate patients and staff on potential side effects. Proper collaboration between all interprofessional healthcare team members, including clinicians, infectious disease specialists, mid-level practitioners, nurses, and pharmacists, helps achieve optimal patient outcomes while minimizing patient risks.